

# Victor E Reuter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11914730/publications.pdf>

Version: 2024-02-01

236  
papers

40,703  
citations

3334

91  
h-index

2629

194  
g-index

243  
all docs

243  
docs citations

243  
times ranked

34127  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Genomic Profiling of Human Prostate Cancer. <i>Cancer Cell</i> , 2010, 18, 11-22.	16.8	3,151
2	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
3	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part A: Renal, Penile, and Testicular Tumours. <i>European Urology</i> , 2016, 70, 93-105.	1.9	2,211
4	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	28.9	1,742
5	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part B: Prostate and Bladder Tumours. <i>European Urology</i> , 2016, 70, 106-119.	1.9	1,323
6	Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. <i>Nature Medicine</i> , 2019, 25, 1301-1309.	30.7	1,320
7	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131-133.	4.5	1,142
8	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	27.0	1,040
9	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. <i>European Urology</i> , 2016, 69, 428-435.	1.9	1,039
10	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11428-11436.	7.1	839
11	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	8.8	746
12	Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma. <i>American Journal of Pathology</i> , 2001, 159, 179-192.	3.8	601
13	SURGICAL MANAGEMENT OF RENAL TUMORS 4 CM. OR LESS IN A CONTEMPORARY COHORT. <i>Journal of Urology</i> , 2000, 163, 730-736.	0.4	581
14	Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions. <i>American Journal of Surgical Pathology</i> , 2003, 27, 750-761.	3.7	562
15	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2002, 167, 1295-1298.	0.4	544
16	An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016, 29, 104-116.	16.8	531
17	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	6.4	523
18	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3967-3972.	7.1	445

#	ARTICLE	IF	CITATIONS
19	Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. American Journal of Surgical Pathology, 2014, 38, 756-767.	3.7	439
20	Correlation of Proton MR Spectroscopic Imaging with Gleason Score Based on Step-Section Pathologic Analysis after Radical Prostatectomy. Radiology, 2005, 234, 804-814.	7.3	386
21	Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum. American Journal of Surgical Pathology, 2007, 31, 1149-1160.	3.7	381
22	Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncology, The, 2007, 8, 304-310.	10.7	370
23	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19458-19463.	7.1	336
24	Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Reports, 2018, 23, 3392-3406.	6.4	324
25	Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. European Radiology, 2015, 25, 2840-2850.	4.5	322
26	PRCC-TFE3 Renal Carcinomas. American Journal of Surgical Pathology, 2002, 26, 1553-1566.	3.7	306
27	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528.	16.8	303
28	Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i> : A Report by MSKCC and the KIRC TCGA Research Network. Clinical Cancer Research, 2013, 19, 3259-3267.	7.0	301
29	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	286
30	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. Journal of Clinical Oncology, 2013, 31, 3133-3140.	1.6	282
31	Renal Carcinomas With the t(6;11)(p21;q12). American Journal of Surgical Pathology, 2005, 29, 230-240.	3.7	279
32	Down-Regulation of Stem Cell Genes, Including Those in a 200-kb Gene Cluster at 12p13.31, Is Associated with In vivo Differentiation of Human Male Germ Cell Tumors. Cancer Research, 2006, 66, 820-827.	0.9	275
33	Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. Journal of Urology, 2013, 190, 407-416.	0.4	264
34	Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. International Journal of Cancer, 1997, 73, 42-49.	5.1	254
35	Tumor Size is Associated With Malignant Potential in Renal Cell Carcinoma Cases. Journal of Urology, 2009, 181, 2033-2036.	0.4	251
36	Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Medicine, 1998, 4, 50-57.	30.7	249

#	ARTICLE	IF	CITATIONS
37	Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2007, 99, 1375-1383.	6.3	248
38	Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Annals of Surgical Oncology, 2004, 11, 71-77.	1.5	244
39	Primary Renal Synovial Sarcoma. American Journal of Surgical Pathology, 2000, 24, 1087-1096.	3.7	235
40	Urachal Carcinoma. American Journal of Surgical Pathology, 2009, 33, 659-668.	3.7	235
41	IMPACT OF SEPARATE VERSUS EN BLOC PELVIC LYMPH NODE DISSECTION ON THE NUMBER OF LYMPH NODES RETRIEVED IN CYSTECTOMY SPECIMENS. Journal of Urology, 2001, 166, 2295-2296.	0.4	232
42	<i>TMPRSS2-ERG</i> Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy. Cancer Research, 2009, 69, 1400-1406.	0.9	231
43	An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. Journal of the National Cancer Institute, 2013, 105, 1862-1870.	6.3	231
44	Translocation Carcinomas of the Kidney After Chemotherapy in Childhood. Journal of Clinical Oncology, 2006, 24, 1529-1534.	1.6	227
45	<i>p53</i> mutations in human bladder cancer: Genotypic versus phenotypic patterns. International Journal of Cancer, 1994, 56, 347-353.	5.1	220
46	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. , 1997, 73, 50-56.		212
47	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clinical Cancer Research, 2014, 20, 1955-1964.	7.0	208
48	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern Pathology, 2010, 23, 1104-1112.	5.5	204
49	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	1.9	202
50	Prostate Cancer: Identification with Combined Diffusion-weighted MR Imaging and 3D <sup>1</sup> H MR Spectroscopic Imaging—Correlation with Pathologic Findings <sup>1</sup> . Radiology, 2008, 246, 480-488.	7.3	200
51	Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. European Urology, 2013, 63, 848-854.	1.9	198
52	Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer, 1993, 71, 3952-3965.	4.1	197
53	Prostate Tumor Volume Measurement with Combined T2-weighted Imaging and Diffusion-weighted MR: Correlation with Pathologic Tumor Volume. Radiology, 2009, 252, 449-457.	7.3	194
54	Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC Markers. American Journal of Surgical Pathology, 2010, 34, 1295-1303.	3.7	181

#	ARTICLE	IF	CITATIONS
55	Transition Zone Prostate Cancer: Metabolic Characteristics at <sup>1</sup> H MR Spectroscopic Imaging—Initial Results. <i>Radiology</i> , 2003, 229, 241-247.	7.3	168
56	TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. <i>American Journal of Surgical Pathology</i> , 2016, 40, 723-737.	3.7	168
57	Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. <i>Modern Pathology</i> , 2011, 24, 1207-1220.	5.5	165
58	A Phase I/II Study for Analytic Validation of <sup>89</sup> Zr- <sup>125</sup> I ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	7.0	163
59	Warty (Condylomatous) Squamous Cell Carcinoma of the Penis. <i>American Journal of Surgical Pathology</i> , 2000, 24, 505-512.	3.7	162
60	Basaloid Squamous Cell Carcinoma: A Distinctive Human Papilloma Virus-Related Penile Neoplasm. <i>American Journal of Surgical Pathology</i> , 1998, 22, 755-761.	3.7	156
61	Renal Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1518-1531.	3.7	154
62	Origins and molecular biology of testicular germ cell tumors. <i>Modern Pathology</i> , 2005, 18, S51-S60.	5.5	149
63	Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. <i>Oncogene</i> , 1998, 16, 2345-2349.	5.9	148
64	Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. <i>Cancer</i> , 2005, 104, 290-298.	4.1	147
65	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	21.4	143
66	A Prostate Cancer “NimboŒ Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
67	Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 1993, 8, 230-236.	2.8	141
68	Immunophenotype of High-Grade Prostatic Adenocarcinoma and Urothelial Carcinoma. <i>Modern Pathology</i> , 2000, 13, 1186-1191.	5.5	141
69	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131.	12.8	140
70	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.5	138
71	Urachal Carcinoma: Contemporary Surgical Outcomes. <i>Journal of Urology</i> , 2007, 178, 74-78.	0.4	137
72	Whole-slide imaging equivalency and efficiency study: experience at a large academic center. <i>Modern Pathology</i> , 2019, 32, 916-928.	5.5	134

#	ARTICLE	IF	CITATIONS
73	Angiomyolipoma With Epithelial Cysts (AMLEC). American Journal of Surgical Pathology, 2006, 30, 593-599.	3.7	129
74	Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology, 2002, 60, 1003-1009.	1.0	128
75	TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Modern Pathology, 2015, 28, 845-853.	5.5	127
76	Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology, 1997, 49, 16-22.	1.0	126
77	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. European Urology, 2015, 67, 198-201.	1.9	122
78	The Pathology of Renal Epithelial Neoplasms. Seminars in Oncology, 2006, 33, 534-543.	2.2	121
79	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	5.5	118
80	Chromophobe Renal Cell Carcinoma. American Journal of Surgical Pathology, 2011, 35, 962-970.	3.7	115
81	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. American Journal of Surgical Pathology, 2016, 40, 1457-1472.	3.7	112
82	Validation of a digital pathology system including remote review during the COVID-19 pandemic. Modern Pathology, 2020, 33, 2115-2127.	5.5	112
83	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. American Journal of Surgical Pathology, 2010, 34, 1367-1376.	3.7	111
84	Prognostic Impact of Histological Subtype on Surgically Treated Localized Renal Cell Carcinoma. Journal of Urology, 2009, 182, 2132-2136.	0.4	110
85	Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors. American Journal of Surgical Pathology, 2014, 38, e35-e49.	3.7	110
86	Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosomes and Cancer, 1989, 1, 83-87.	2.8	109
87	TFEB-amplified Renal Cell Carcinomas. American Journal of Surgical Pathology, 2016, 40, 1484-1495.	3.7	109
88	ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. European Urology, 2013, 63, 16-35.	1.9	107
89	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	5.5	106
90	A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. Modern Pathology, 2015, 28, 1603-1612.	5.5	100

#	ARTICLE	IF	CITATIONS
91	Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1. <i>Cell Metabolism</i> , 2020, 31, 105-114.e3.	16.2	100
92	NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. <i>American Journal of Surgical Pathology</i> , 2018, 42, 636-645.	3.7	97
93	Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 377-382.	3.7	96
94	Neuroendocrine Differentiation in Metastatic Prostatic Adenocarcinoma. <i>Journal of Urology</i> , 1994, 151, 914-919.	0.4	95
95	TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. <i>Modern Pathology</i> , 2010, 23, 1325-1333.	5.5	95
96	Nested Variant of Urothelial Carcinoma: A Clinicopathologic and Immunohistochemical Study of 12 Cases. <i>Modern Pathology</i> , 2003, 16, 1289-1298.	5.5	93
97	RBM10-TFE3 Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 655-662.	3.7	92
98	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. <i>Cancer Discovery</i> , 2011, 1, 35-43.	9.4	91
99	t(6;11) Renal Cell Carcinoma (RCC). <i>American Journal of Surgical Pathology</i> , 2014, 38, 604-614.	3.7	91
100	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	2.0	89
101	Detection of Prostate Cancer with MR Spectroscopic Imaging: An Expanded Paradigm Incorporating Polyamines. <i>Radiology</i> , 2007, 245, 499-506.	7.3	88
102	Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 3712-3720.	7.0	88
103	Glutathione S-transferase Pi (GST-pi) Class Expression by Immunohistochemistry in Benign and Malignant Prostate Tissue. <i>Journal of Urology</i> , 1997, 157, 673-676.	0.4	86
104	Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. <i>Modern Pathology</i> , 2009, 22, 1066-1074.	5.5	85
105	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	7.0	85
106	Feasibility of Radical Prostatectomy After Neoadjuvant Chemohormonal Therapy for Patients With High Risk or Locally Advanced Prostate Cancer: Results of a Phase I/II Study. <i>Journal of Urology</i> , 2004, 171, 709-713.	0.4	83
107	Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 5442-5447.	7.0	81
108	Performance Characteristics of MR Imaging in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study. <i>Radiology</i> , 2012, 265, 478-487.	7.3	81

#	ARTICLE	IF	CITATIONS
109	Implementation of Digital Pathology Offers Clinical and Operational Increase in Efficiency and Cost Savings. Archives of Pathology and Laboratory Medicine, 2019, 143, 1545-1555.	2.5	81
110	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology, 2019, 76, 754-764.	1.9	80
111	Diagnostic Significance of Mitochondria in Four Types of Renal Epithelial Neoplasms: An Ultrastructural Study of 60 Tumors. Ultrastructural Pathology, 1997, 21, 409-417.	0.9	78
112	Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. , 1997, 33, 225-232.		78
113	The pathology of bladder cancer. Urology, 2006, 67, 11-17.	1.0	73
114	Somatic mutation of fibroblast growth factor receptorâ€³ (<i>FGFR3</i>) defines a distinct morphological subtype of highâ€³grade urothelial carcinoma. Journal of Pathology, 2011, 224, 270-279.	4.5	73
115	Validating Whole Slide Imaging Systems for Diagnostic Purposes in Pathology. Archives of Pathology and Laboratory Medicine, 2022, 146, 440-450.	2.5	73
116	Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage. Cancer Research, 2008, 68, 6054-6058.	0.9	71
117	Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. Journal of Clinical Oncology, 2009, 27, 5240-5247.	1.6	70
118	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Nonâ€³Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 3846-3853.	1.6	69
119	Comparative genomic hybridization for genetic analysis of renal oncocytomas. Genes Chromosomes and Cancer, 1996, 17, 199-204.	2.8	65
120	Sex Cordâ€³Stromal Tumors of the Testis With Entrapped Germ Cells. American Journal of Surgical Pathology, 2000, 24, 535-542.	3.7	65
121	MECHANISMS OF PROSTATIC STROMAL INVASION IN PATIENTS WITH BLADDER CANCER: CLINICAL SIGNIFICANCE. Journal of Urology, 2001, 165, 1117-1120.	0.4	63
122	Differential Diagnosis of Renal Tumors With Papillary Architecture. Advances in Anatomic Pathology, 2011, 18, 120-131.	4.3	63
123	Abnormalities of 2q: A common genetic link between rhabdomyosarcoma and hepatoblastoma?. Genes Chromosomes and Cancer, 1991, 3, 122-127.	2.8	62
124	Bladder Neck Involvement in Pathological Stage pT4 Radical Prostatectomy Specimens is Not An Independent Prognostic Factor. Journal of Urology, 2002, 168, 2011-2015.	0.4	62
125	Clinical Outcome of Patients with T1 Micropapillary Urothelial Carcinoma of the Bladder. Journal of Urology, 2014, 192, 702-707.	0.4	61
126	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nature Communications, 2017, 8, 15165.	12.8	61



#	ARTICLE	IF	CITATIONS
127	Differential diagnosis of renal tumours with clear cell histology. <i>Pathology</i> , 2010, 42, 374-383.	0.6	59
128	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. <i>American Journal of Surgical Pathology</i> , 2019, 43, 920-927.	3.7	59
129	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Journal of Urology</i> , 2020, 203, 1122-1127.	0.4	58
130	Gene expression-based classification of nonseminomatous male germ cell tumors. <i>Oncogene</i> , 2005, 24, 5101-5107.	5.9	57
131	Clinical Stage T1c Prostate Cancer: Evaluation with Endorectal MR Imaging and MR Spectroscopic Imaging. <i>Radiology</i> , 2009, 253, 425-434.	7.3	57
132	Long-term follow-up of bilateral sporadic renal tumors. <i>Urology</i> , 2003, 61, 921-925.	1.0	51
133	Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases. <i>Modern Pathology</i> , 2017, 30, 1476-1488.	5.5	51
134	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.	0.4	49
135	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2018, 36, 3553-3559.	1.6	49
136	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. <i>Modern Pathology</i> , 2019, 32, 1344-1358.	5.5	49
137	Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1992, 5, 21-29.	2.8	46
138	Comedonecrosis Revisited. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1036-1041.	3.7	44
139	Intrarenal Schwannoma: A Report of Four Cases Including Three Cellular Variants. <i>Modern Pathology</i> , 2000, 13, 851-856.	5.5	43
140	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	3.1	43
141	Integrating digital pathology into clinical practice. <i>Modern Pathology</i> , 2022, 35, 152-164.	5.5	42
142	Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. <i>Modern Pathology</i> , 2012, 25, 1534-1542.	5.5	41
143	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. <i>Histopathology</i> , 2015, 67, 313-324.	2.9	41
144	Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder Cancer. <i>Diagnostic Molecular Pathology</i> , 1993, 2, 4-13	2.1	40

#	ARTICLE	IF	CITATIONS
145	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	3.1	40
146	The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 914-919.	0.4	39
147	Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases. <i>Modern Pathology</i> , 2019, 32, 1329-1343.	5.5	39
148	Integrated digital pathology at scale: A solution for clinical diagnostics and cancer research at a large academic medical center. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 1874-1884.	4.4	39
149	TFEB Expression Profiling in Renal Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1445-1461.	3.7	38
150	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. <i>Journal of Pathology</i> , 2019, 248, 260-265.	4.5	37
151	Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 194, 310-315.	0.4	36
152	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689.	0.4	36
153	Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. <i>Cancer Immunity</i> , 2003, 3, 19.	3.2	36
154	Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1562-1570.	3.7	35
155	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. <i>European Urology</i> , 2021, 79, 468-477.	1.9	35
156	Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. , 1996, 69, 110-113.		34
157	Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles. <i>Clinical Cancer Research</i> , 2009, 15, 3842-3849.	7.0	34
158	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1571-1584.	3.7	34
159	Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC). <i>American Journal of Surgical Pathology</i> , 2020, 44, 901-916.	3.7	34
160	Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features. <i>American Journal of Surgical Pathology</i> , 2018, 42, 767-777.	3.7	33
161	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 373-379.e4.	1.9	33
162	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , 1998, 17, 761-767.	5.9	31

#	ARTICLE	IF	CITATIONS
163	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2020, 44, 673-680.	3.7	31
164	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. ELife, 2019, 8, .	6.0	31
165	Molecular genetics of testicular germ cell tumors. American Journal of Cancer Research, 2012, 2, 153-67.	1.4	31
166	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	3.1	30
167	Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. Journal of Urology, 2019, 201, 77-83.	0.4	30
168	Correlation of MR Imaging and MR Spectroscopic Imaging Findings with Ki-67, Phospho-Akt, and Androgen Receptor Expression in Prostate Cancer. Radiology, 2009, 250, 803-812.	7.3	29
169	Non-urothelial carcinomas of the bladder. Histopathology, 2019, 74, 97-111.	2.9	29
170	Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile. Modern Pathology, 2019, 32, 701-709.	5.5	29
171	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	3.1	28
172	EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. Modern Pathology, 2021, 34, 1921-1934.	5.5	28
173	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. Journal of Urology, 2020, 203, 1117-1121.	0.4	28
174	Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. , 2000, 88, 407-415.		27
175	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 2018, 77, 63-69.	2.0	27
176	Estrogen and progesterone-receptor-positive stroma as a non-tumorous proliferation in kidneys: a possible metaplastic response to obstruction. Modern Pathology, 2008, 21, 60-65.	5.5	26
177	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	4.3	23
178	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	3.7	22
179	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer, 2020, 126, 5247-5255.	4.1	22
180	Flow Cytometry and Cytology as Response Indicators to M-VAC (Methotrexate, Vinblastine,) Tj ETQq0 0 0 rgBT /Overlock 10 If 50 62 Td	0.4	21

#	ARTICLE	IF	CITATIONS
181	Urothelial neoplasms in pediatric and young adult patients: A large single-center series. <i>Journal of Pediatric Surgery</i> , 2018, 53, 306-309.	1.6	21
182	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	1.9	21
183	<sc><i>TMPRSS2</i></sc> rearrangement in dominant anterior prostatic tumours: incidence and correlation with <sc>ERG</sc> immunohistochemistry. <i>Histopathology</i> , 2013, 63, 279-286.	2.9	20
184	Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 535-540.	0.4	19
185	Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 159, 33-38.	0.6	18
186	Digital Pathology Operations at an NYC Tertiary Cancer Center During the First 4 Months of COVID-19 Pandemic Response. <i>Academic Pathology</i> , 2021, 8, 23742895211010276.	1.1	18
187	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , 2015, 10, e0142846.	2.5	18
188	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.	1.6	17
189	Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla. <i>Magnetic Resonance Imaging</i> , 2019, 55, 93-102.	1.8	17
190	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1596-1607.	5.5	17
191	Blood group antigens in normal and neoplastic urothelium. <i>Journal of Cellular Biochemistry</i> , 1992, 50, 50-55.	2.6	16
192	EVALUATION OF NEW RESECTOSCOPE LOOP FOR TRANSURETHRAL RESECTION OF BLADDER TUMORS. <i>Journal of Urology</i> , 1998, 159, 2067-2068.	0.4	16
193	Regarding the Focal Treatment of Prostate Cancer: Inference of the Gleason Grade From Magnetic Resonance Spectroscopic Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 110-114.	0.8	16
194	(Re) Defining the High-Power Field for Digital Pathology. <i>Journal of Pathology Informatics</i> , 2020, 11, 33.	1.7	16
195	An Exploratory Study of Endorectal Magnetic Resonance Imaging and Spectroscopy of the Prostate as Preoperative Predictive Biomarkers of Biochemical Relapse After Radical Prostatectomy. <i>Journal of Urology</i> , 2010, 184, 2320-2327.	0.4	15
196	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29.	0.4	15
197	Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 445-456.	5.5	15
198	Expression of blood group antigens in bladder cancer: Current concepts. <i>Journal of Surgical Oncology</i> , 1992, 8, 308-315.	1.4	14

#	ARTICLE	IF	CITATIONS
199	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. <i>Modern Pathology</i> , 2022, 35, 825-835.	5.5	14
200	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	7.0	12
201	<i>PTEN</i> Loss with <i>ERG</i> Negative Status is Associated with Lethal Disease after Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 203, 344-350.	0.4	12
202	Workgroup 3: Current prognostic factors and their relevance to staging. , 1996, 78, 369-371.		11
203	The pre and post chemotherapy pathologic spectrum of germ cell tumors. <i>Chest Surgery Clinics of North America</i> , 2002, 12, 673-694.	0.7	11
204	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	1.6	11
205	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288.	3.1	11
206	Progression of T1 bladder tumors. , 1999, 86, 908-909.		10
207	Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. <i>Human Pathology</i> , 2020, 103, 1-13.	2.0	10
208	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 507-516.	3.9	10
209	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020, 4, 1307-1320.	3.0	9
210	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , 2021, 274, e1099-e1107.	4.2	9
211	Intraoperative touch-imprint cytology of germ cell neoplasms. , 1996, 14, 393-394.		8
212	Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities. <i>Journal of Pathology</i> , 2020, 250, 464-465.	4.5	8
213	Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 961-968.	0.4	7
214	Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. <i>Journal of Urology</i> , 2022, 208, 309-316.	0.4	7
215	The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by <sup>111</sup> Indium-labeled humanized monoclonal antibody 3S193. <i>European Journal of Radiology</i> , 2008, 67, 292-299.	2.6	6
216	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. <i>JCO Precision Oncology</i> , 2022, , .	3.0	6

#	ARTICLE	IF	CITATIONS
217	Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. <i>Histopathology</i> , 2022, 81, 246-254.	2.9	6
218	Granular Cell Tumor of the Bladder: A Report of Six Cases. <i>Urology</i> , 2018, 121, 203.e1-203.e5.	1.0	5
219	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. <i>Urology</i> , 2020, 144, 111-116.	1.0	5
220	Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?. <i>Journal of Urology</i> , 2018, 199, 1502-1509.	0.4	4
221	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1141-1149.	1.3	4
222	TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas. <i>Endocrine Pathology</i> , 2022, 33, 304-314.	9.0	4
223	Efficient Visualization of Whole Slide Images in Web-based Viewers for Digital Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 1273-1280.	2.5	4
224	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2019, 75, 453-467.	2.9	3
225	Comparative genomic hybridization for genetic analysis of renal oncocytomas. <i>Genes Chromosomes and Cancer</i> , 1996, 17, 199-204.	2.8	3
226	A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. <i>Human Pathology</i> , 2019, 88, 48-59.	2.0	2
227	Clinical utility of subclassifying positive surgical margins at radical prostatectomy. <i>BJU International</i> , 2021, , .	2.5	2
228	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.4	2
229	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. <i>International Journal of Cancer</i> , 1997, 73, 50-56.	5.1	2
230	Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer. <i>World Journal of Radiology</i> , 2017, 9, 134.	1.1	1
231	Practice Patterns in Reporting Tertiary Grades at Radical Prostatectomy: Survey of a Large Group of Experienced Urologic Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 356-360.	2.5	1
232	Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. <i>Cancer</i> , 2000, 88, 407-415.	4.1	1
233	Adult Wilms Tumor. <i>American Journal of Surgical Pathology</i> , 2022, Publish Ahead of Print, .	3.7	1
234	DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient. <i>JCO Precision Oncology</i> , 2022, , .	3.0	1

#	ARTICLE	IF	CITATIONS
235	Anatomy of the Urinary Bladder Revisited: Implications for Diagnosis and Staging of Bladder Cancer. , 2015, , 173-187.		0
236	Reply by Authors. Journal of Urology, 2020, 203, 1121-1121.	0.4	0